Search results
TAR-210 results show 90% recurrence-free survival and 90% complete response in patients with...
Benton Courier· 2 days agoUpdated results reinforce the potential of TAR-210 to transform treatment of non–muscle-invasive ...
TAR-200 monotherapy shows greater than 80% complete response rate in patients with high-risk...
Valley City Times Record· 4 days ago"The high complete response rate and durability of these responses observed in patients treated with...
Hope and Healing: Bladder Cancer Awareness Month Starts Today
FOX 4 Kansas City· 6 days agoThe Bladder Cancer Advocacy Network (BCAN) is proud to announce the start of Bladder Cancer...
New Cancer 'Missile' Drugs May Be More Effective Than Traditional Chemotherapy
Verywell Health via Yahoo News· 5 days agoHis recent Phase 1 trial showed the combination of two drugs showed high efficacy and was reasonably...
The nine things every man should know about prostate cancer
The Telegraph via Yahoo News· 6 days agoOpening up about their below-the-belt health is not a conversation every man wants to have with his...
Fighting Cancer: A Basic Guide To Checkpoint Inhibitors
Forbes· 2 days agoThis article is part of an ongoing series on novel cancer advances, including immunotherapies such...
Sumitomo Pharma Presents Urology and Oncology Data at AUA 2024 Annual Meeting
WTRF Wheeling· 7 hours agoFollowing the podium presentation at AUA, these...
...Study of EG-70 in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in situ at...
Fort Wayne Journal Gazette· 5 days ago(Nasdaq: ENGN) or ("enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral lead program EG-70 is in a pivotal study for BCG-unresponsive non-muscle invasive < ...
High Response Rates With Gene Therapies for BCG-Unresponsive Bladder Cancer
MedPage Today· 4 days agoThree-fourths of patients had complete responses, which proved to be durable in most cases
CG follows big IPO with new results for bladder cancer drug
BioPharma Dive via Yahoo Finance· 4 days agoNewly disclosed Phase 3 results presented Friday match findings the biotech disclosed last year,...